• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

July 3, 2012

View Archived Issues

BMS, AstraZeneca Join Forces in $7B Combo Deal for Amylin

Bristol Myers Squibb Co., of New York, will realize operating synergies and tax benefits in addition to gaining access to Amylin Pharmaceuticals Inc.'s GLP-1 franchise, executives said in a Monday morning conference call regarding the pharma giant's acquisition of San Diego-based Amylin and partnership agreement with AstraZeneca plc. Read More

AstraZeneca: Joint Approach in Amylin Deal 'Made Sense'

After Bristol-Myers Squibb Co. announced the acquisition of Amylin Pharmaceuticals Inc. late Friday afternoon, it emerged that the deal is to be a 50-50 joint purchase with AstraZeneca plc, and that all Amylin's assets are to be placed in the Type II diabetes collaboration the two pharma companies established in January 2007. Read More

Phase III UMEC/VI Studies a Win for Theravance/GSK

Regulatory filings appear to be the next step for the LAMA/LABA bronchodilator combination of umeclidinium bromide (UMEC, or GSK573719) and vilanterol (VI), under development by GlaxoSmithKline plc and longtime partner Theravance Inc. The companies reported top-line results early Monday indicating the first four of seven Phase III studies of the investigational therapy showed superiority against both placebo and current standard of care in chronic obstructive pulmonary disease (COPD). Read More

Developmental Stalwart Wnt Helps Keep Fat Cells Skinny

Wnt is a signaling pathway that plays critical roles in development, and its proteins can go awry in many cancers. Now, researchers from the University of Michigan have gained new insights into the relationship between Wnt signaling, metabolism and mitochondria. Read More

Gemmus Helping Immune System Pace Itself Against Flu

San Francisco-based start-up Gemmus Pharma Inc. closed an angel-backed Series A funding round of $1.45 million last week. The company expects the money and the planned second tranche will take its lead compound, GP1001, to a planned 2014 investigational new drug application (IND). Read More

Holiday Notice

BioWorld's offices will be closed Wednesday, July 4, in observance of the Independence Day holiday in the U.S. Read More

Stock Movers

Read More

Clinic Roundup

• Protalix BioTherapeutics Inc., of Carmiel, Israel, reported clinical data for taliglucerase alfa showing that at 36 months, patients with Gaucher disease had significant improvement in bone marrow fat fraction from baseline, with a mean change of 92 percent. Read More

Other News To Note

• Cleveland BioLabs Inc., of Buffalo, N.Y., and its subsidiary Incuron LLC, of Moscow, said a study demonstrating that CBL0137 counteracted tumor formation in a mouse spontaneous breast cancer model was published online in Cancer Prevention Research. Read More

Financings Roundup

• Corcept Therapeutics Inc., of Menlo Park, Calif., disclosed plans for an underwritten public offering of 11 million shares of common stock. Read More

Pharma: Other News To Note

• K-V Pharmaceutical Co., of St. Louis, said the FDA provided further guidance to health care providers and pregnant women at high risk for recurrent preterm birth. Read More

Pharma: Clinic Roundup

• Teva Pharmaceutical Industries Ltd., of Jerusalem, presented Phase III results showing that lipegfilgrastim and balugrastim, long-acting granulocyte colony-stimulating factors, achieved the primary endpoint in breast cancer studies, demonstrating reduction in the duration of severe neutropenia in cycle 1, comparable to Neulasta (pegfilgrastim, Amgen Inc.) in both efficacy and safety measures. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe